Clinoleic 20% Injection (Plastic Bag)

Adult administration

Administered intravenously. 1 day lipid 1g - maximum 2g/body kg. Initially, administration should be done slowly, ensuring that during the first 10 minutes lipid does not exceed 0.1g or 0.5ml (10 drops) per minute, then gradually speed up to reach optimal rate after 30 minutes. Do not exceed lipid 0.15g/kg/hour (0.75ml/kg/hour). Typical lipid dosage.

Child administration

Continuous infusion over 24 hours is required. Daily dosage per kg of body weight should not exceed 3g, and the infusion rate must not exceed 0.15g/body kg/h. The daily dose should gradually increase during the first week of administration.

Care should be taken when administering this drug to premature infants and low-birth-weight infants as it may increase serum free fatty acid levels. Patients with allergies, especially those sensitive to egg, peanut, and soybean proteins, should not use this medication. This drug should not be administered to patients with metabolic disorders, severe dyslipidemia, acute pancreatitis, myocardial infarction, or metabolic instability. Rarely, allergic reactions may occur upon administration of this medication, so if symptoms such as sweating, chills, headache, or apnea appear, use should be immediately discontinued. Long-term use may lead to liver dysfunction, thrombocytopenia, hyperglycemia, and hypertriglyceridemia, hence regular check-ups are required. As the fat overload syndrome may occur, appropriate dosing should be adhered to, and the patient's condition should be closely monitored. If serious hypersensitivity reactions such as anaphylaxis occur, administration must be immediately stopped, and appropriate measures taken. Serum triglyceride levels should be checked daily and must not exceed 3 mmol/L. During non-oral nutritional therapy, liver function tests, blood sugar, electrolytes, and coagulation status should be routinely monitored. Patients with excessive fluid or electrolyte imbalances or metabolic disorders should correct their condition before administering this drug. Fat emulsion should be administered along with carbohydrates and amino acids to prevent metabolic acidosis. In patients with acute kidney dysfunction, pulmonary edema, or heart failure, fluid balance should be carefully managed. When administering to neonates or children, careful management under specialist supervision is required, particularly in cases of hyperbilirubinemia, where bilirubin levels must be monitored closely. There is a risk of infection and sepsis associated with intravenous infusion, thus aseptic techniques and catheter management should be strictly followed. Patients with liver failure are at risk of deteriorating liver function; hence frequent clinical and laboratory tests should be conducted considering the possibility of liver disease associated with non-oral nutrition. Patients with blood coagulation disorders or anemia should closely observe blood counts and coagulation factors and daily check for symptoms of thrombophlebitis at the intravenous injection site. In severely malnourished patients, refeeding syndrome may occur when nutrition is resumed, so nutrition should be gradually increased with careful monitoring. When administering to neonates and infants under the age of 2, exposure to light should be avoided. It is important to verify compatibility and carefully mix this medication when combined with other drugs and to properly mix before combining. Except in special cases, it is safest for women during pregnancy or breastfeeding not to use this medication. After administration, lipid components may affect blood test results, thus caution is advised. In cases of overdose, symptoms such as fever, vomiting, liver dysfunction, and blood coagulation disorders may occur, and administration should be stopped or reduced as necessary. This medication is for single use; check the packaging and homogeneity of the solution before use. After opening, use immediately, do not reuse leftover medication, and dispose of used equipment properly. To prevent air embolism during administration, any residual gas in the injection solution must be completely removed, and continuous connection should be avoided. Store this medication in a sealed container to prevent contact with air. Additionally, avoid freezing and maintain the temperature below 25 degrees Celsius. It is important to store it away from direct sunlight.

Serious side effects

Hives, severe swelling (edema), difficulty breathing, jaundice, liver enlargement, severe allergic reactions, severe rashes with high fever, blisters, skin peeling, pain in oral/eye mucosa, severe sepsis, severe swelling, increased blood pressure, serious neurological symptoms (headaches, seizures, confusion, visual disturbances, paralysis).

Mild side effects

Nausea, vomiting, sweating, chills, headache, apnea, thrombocytopenia, hyperglycemia, abdominal distension, abdominal pain, upper abdominal discomfort, diarrhea, cholestasis, pruritus, increased serum bilirubin, increased conjugated bilirubin, elevated liver enzymes, elevated serum triglycerides, decreased mean arterial pressure, reduced INR, coagulation disorders, anemia, leukopenia, thrombophlebitis, and symptoms related to infection and sepsis.

This medication should be stored in a sealed container to avoid contact with air. Also, care should be taken to prevent the medication from freezing, maintaining a temperature below 25 degrees Celsius. It is important to store it away from direct sunlight.

Appearance

A colorless, transparent solution in a plastic bag with a unique odor, which is a milky-white homogeneous solution.

Package unit

100, 250, 500ml/bag